We developed a wide panel of mAbs against various epitopes of native human complement system proteins, many of them with potential to be used in therapy development.
The mAb panel was generated via Biosystems’s unique and patented mAb discovery technology, using human blood and without applying any recombinant technology (commonly used by others).
The current library consists of close to 200 mAbs, of which 42 showed inhibition in our assays.
